Enhancement of rAAV titers via inhibition of the interferon signaling cascade in transfected HEK293 suspension cultures

Abstract

AbstractThe production of recombinant adeno‐associated virus (rAAV) for gene therapy applications relies on the use of various host cell lines, with suspension‐grown HEK293 cells being the preferred expression system due to their satisfactory rAAV yields in transient transfections. As the field of gene therapy continues to expand, there is a growing demand for efficient rAAV production, which has prompted efforts to optimize HEK293 cell line productivity through engineering. In contrast to other cell lines like CHO cells, the transcriptome of HEK293 cells during rAAV production has remained largely unexplored in terms of identifying molecular components that can enhance yields.In our previous research, we analyzed global regulatory pathways and mRNA expression patterns associated with increased rAAV production in HEK293 cells. Our data revealed substantial variations in the expression patterns between cell lines with low (LP) and high‐production (HP) rates. Moving to a deeper layer for a more detailed analysis of inflammation‐related transcriptome data, we detected an increased expression of interferon‐related genes in low‐producing cell lines.Following upon these results, we investigated the use of Ruxolitinib, an interferon pathway inhibitor, during the transient production of rAAV in HEK293 cells as potential media additive to boost rAAV titers. Indeed, we find a two‐fold increase in rAAV titers compared to the control when the interferon pathways were inhibited. In essence, this work offers a rational design approach for optimization of HEK293 cell line productivity and potential engineering targets, ultimately paving the way for more cost‐efficient and readily available gene therapies for patients.